Key Biotech Terms Explained
Essential terminology you need to understand Biotech news. Each term is explained in plain language with context for how it appears in current reporting.
CRISPR
Gene-editing platform that modifies DNA sequences with high precision using guide RNA and Cas enzymes; enables therapeutic correction of inherited mutations
mRNA Therapy
Messenger RNA technology delivering coded instructions to ribosomes for in-cell protein synthesis; backbone of next-generation vaccines and oncology immunotherapies
FDA Approval
United States Food and Drug Administration regulatory clearance authorizing commercial distribution following review of safety, efficacy, and manufacturing controls
Clinical Trial Phases
Sequential stages of human testing — Phase I evaluates safety in healthy volunteers, Phase II tests efficacy in patients, Phase III confirms efficacy at scale, Phase IV monitors post-market
Biosimilar
Biological product structurally and functionally analogous to an originator reference product; expands access to monoclonal antibodies and biologics after patent expiry
CAR-T Therapy
Chimeric Antigen Receptor T-cell immunotherapy where patient T-cells are engineered to attack tumor antigens; revolutionary treatment for hematologic malignancies
Orphan Drug
Pharmaceutical developed for rare conditions affecting under 200,000 patients in the United States; receives extended exclusivity and tax incentives
IND Application
Investigational New Drug submission required before commencing human clinical trials in the United States; describes pharmacology, manufacturing, and trial protocols
BLA Submission
Biologics License Application filed with the FDA to seek marketing authorization for biological products including vaccines, monoclonal antibodies, and cell therapies
NDA Filing
New Drug Application requesting FDA approval for small-molecule pharmaceutical products; combines pharmacology, manufacturing chemistry, clinical safety, and labeling
Phase III Readout
Public disclosure of pivotal late-stage clinical trial results; typically catalyzes substantial movement in biotech equities
Pharmacokinetics
Study of how drug compounds move through the body — absorption, distribution, metabolism, excretion (ADME) — informing dosing and formulation design
Pharmacodynamics
Examination of biochemical and physiological effects of drugs on the body, including receptor binding, signaling cascades, and dose-response relationships
Drug-Target Engagement
Quantitative measurement of how a therapeutic compound binds and modulates its intended biological target in living tissue
ADC Conjugate
Antibody-Drug Conjugate combining tumor-targeting antibody with cytotoxic payload through chemical linker, delivering chemotherapy precisely to cancer cells
GLP-1 Receptor Agonist
Drug class mimicking glucagon-like peptide hormones to stimulate insulin secretion; transformative for diabetes, obesity, and cardiovascular indications
Real-World Evidence
Clinical insights derived from analysis of patient outcomes outside controlled trial settings — claims data, electronic records, registries, wearables
Companion Diagnostic
Test required for selecting patients eligible for specific targeted therapies; common in precision oncology to confirm biomarker presence
Breakthrough Designation
FDA expedited review status for therapies addressing serious conditions with preliminary evidence of substantial improvement over existing treatments
Priority Review Voucher
Tradeable FDA voucher granted for rare pediatric disease or tropical disease approvals; entitles holder to expedited 6-month review
Specialty Pharmacy
Distribution channel handling complex therapeutics requiring patient management, cold-chain storage, prior authorization, or controlled administration
Pharmacy Benefit Manager
PBM intermediary negotiating drug prices, managing formularies, and processing claims between insurers, pharmacies, and pharmaceutical manufacturers
IPR Patent Challenge
Inter Partes Review proceeding before the Patent Trial and Appeal Board challenging issued biotech patents; common pre-launch competitive tactic
Biomanufacturing CDMO
Contract Development and Manufacturing Organization providing outsourced production capacity for biological therapeutics, gene therapies, and vaccines
Patient Advocacy Organization
Nonprofit groups representing disease communities; influential in trial recruitment, regulatory engagement, and post-approval access
How These Terms Appear in Our Coverage
Our editorial process surfaces these terms in context across daily intelligence briefs. Our automated pipeline classifies topics, identifies entities, and assesses sentiment using a controlled vocabulary aligned with this glossary. Multi-source verification links each story to its original source articles, and quality control checks ensure accurate framing before publication. See our methodology page for full detail on how we select, score, and verify reporting across Biotech.
Source diversity is essential: we monitor regulatory bulletins, peer-reviewed journals, equity research, primary corporate communications, and trade publications. Each story shows the source count so readers can assess reliability independently. Stories tagged with single-source reporting are clearly marked. Our intelligence pipeline favors corroborated coverage over single-outlet claims, prioritizing items with broad attestation across independent reporting.
Stay Informed
These terms appear frequently in Biotech reporting. Bookmark this page as a quick reference when reading our latest intelligence briefs.